Subsidy Information and Financing Scheme MAFDarolutamide Tablet 300 mg 1) Darolutamide in combination with androgen deprivation therapy for treating patients with high-ri... See all × MAFDarolutamide Tablet 300 mg 1) Darolutamide in combination with androgen deprivation therapy for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) Darolutamide in combination with androgen deprivation therapy for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). MSHLDarolutamide Tablet 300 mg 1) Darolutamide in combination with androgen deprivation therapy (ADT) for treating patients with h... See all × MSHLDarolutamide Tablet 300 mg 1) Darolutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) Darolutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Drug Guidance for Subsidy 13/09/2024 Darolutamide for treating prostate cancer The Ministry of Health’s Drug Advisory Committee has recommended: Darolutamide 300 mg tablet ... See all × 13/09/2024 Darolutamide for treating prostate cancer The Ministry of Health’s Drug Advisory Committee has recommended: Darolutamide 300 mg tablet in combination with androgen deprivation therapy for treating patients with: high-risk non-metastatic castration-resistant prostate cancer; and metastatic hormone-sensitive prostate cancer in view of the acceptable pricing proposal by the company and potential cost savings to the healthcare system. Funding status RDarolutamide 300 mg tablet is recommended for inclusion on the Medication Assistance Fund for the abovementioned indications from 1 November 2024. Clinical indications, subsidy class and MediShield Life claim limits for darolutamide are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 300 mg Changi General Hospital Khoo Teck Puat Hospital National Cancer Centre Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital